Needle-free vaccine delivery

Expert Opinion on Drug Delivery

Volumn 4, Issue 5, 2007, Pages 459-474

  Kersten, Gideon ^a   Hirschberg, Hoang ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Adjuvants; Dermal vaccination; Jet injection; Mucosal vaccination; Needle free; Vaccine

Indexed keywords

ALANYL DEXTRO ISOGLUTAMINE 1 ADAMANTYLAMIDE; ANTHRAX VACCINE; BIOVIRX; CHITOSAN; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DNA VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIPOSOME; LIVE VACCINE; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MEASLES VACCINE; NASALFLU; ORAL POLIOMYELITIS VACCINE; PLACEBO; POLYSACCHARIDE VACCINE; ROTAVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TYPHUS VACCINE; UNCLASSIFIED DRUG; VIROSOME; VIRUS VECTOR;

ANTHRAX; BIOLOGICAL WARFARE; CHOLERA; CLINICAL TRIAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG IMPURITY; DRUG MARKETING; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EPIDEMIC; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; INJECTION SITE PAIN; INTESTINE INTUSSUSCEPTION; JET INJECTOR; MASS IMMUNIZATION; MEASLES; NEEDLE; NEEDLESTICK INJURY; NONHUMAN; PANDEMIC; PERTUSSIS; POLIOMYELITIS; PREVENTIVE HEALTH SERVICE; REGISTRATION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SEXUALLY TRANSMITTED DISEASE; SMALLPOX; SYRINGE; TETANUS; TYPHOID FEVER; TYPHUS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; DRUG ADMINISTRATION ROUTES; DRUG COMBINATIONS; HUMANS; INJECTIONS, JET; MUCOUS MEMBRANE; NEEDLES; TECHNOLOGY, PHARMACEUTICAL; VACCINATION; VACCINES;

EID: 34948825523     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.5.459     Document Type: Review

References (139)

1. BURGESS DC, BURGESS MA, LEASK J: The MMR vaccination and autism controversy in United Kingdom 1998 - 2005: inevitable community outrage or a failure of risk communication? Vaccine (2006) 24(18):3921-3928.
2. RENNE E: Perspectives on polio and immunization in Northern Nigeria. Soc. Sci. Med. (2006) 63(7):1857-1869.
3. GIUDICE EL, CAMPBELL JD: Needle-free vaccine delivery. Adv. Drug Deliv. Rev. (2006) 58(1):68-89.
4. AZAD N, ROJANASAKUL Y: Vaccine delivery - current trends and future. Curr Drug Deliv. (2006) 3(2):137-146.
5. O'HAGAN DT, RAPPUOLI R: Novel approaches to pediatric vaccine delivery. Adv. Drug Deliv. Rev. (2006) 58(1):29-51.
6. MITRAGOTRI S: Immunization without needles. Nat. Rev. Immunol. (2005) 5(12):905-916.
7. BAXTER J, MITRAGOTRI S: Needle-free liquid jet injections: mechanisms and applications. Expert Rev. Med. Devices (2006) 3(5):565-574.
8. MITRAGOTRI S: Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. (2006) 5(7):543-548.
9. CEVC G: Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug Deliv. Rev. (2004) 56(5):675-711.
10. BENSON HA: Transfersomes for transdermal drug delivery. Expert Opin. Drug Deliv. (2006) 3(6):727-737.
11. CHOI MJ, KIM JH, MAIBACH HI: Topical DNA vaccination with DNA/lipid based complex. Curr. Drug Deliv. (2006) 3(1):37-45.
12. DEAN HJ: Alternative routes of influenza vaccine delivery. Expert Opin. Drug Deliv. (2006) 3(5):557-561.
13. GLENN GM, KENNEY RT: Mass vaccination: solutions in the skin. Curr Top. Microbiol. Immunol. (2006) 304:247-268.
14. PARTIDOS CD: Delivering vaccines into the skin without needles and syringes 3. Expert Rev. Vaccines (2003) 2(6):753-761.
15. PRAUSNITZ MR: Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. (2004) 56(5):581-587.
16. ALPAR HO, SOMAVARAPU S, ATUAH KN, BRAMWELL VW: Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. (2005) 57(3):411-430.
17. DE MAGISTRIS MT: Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev. (2006) 58(1):52-67.
18. HOLMGREN J, CZERKINSKY C: Mucosal immunity and vaccines. Nat. Med. (2005) 11(4 Suppl.):S45-S53.
19. ILLUM L: Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. (2007) 96(3):473-483.
20. LAVELLE EC, O'HAGAN DT: Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug Deliv. (2006) 3(6):747-762.
21. LU D, HICKEY AJ: Pulmonary vaccine delivery. Expert Rev. Vaccines (2007) 6(2):213-226.
22. NEUTRA MR, KOZLOWSKI PA: Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. (2006) 6(2):148-158.
23. VAJDY M, SINGH M: The role of adjuvants in the development of mucosal vaccines. Expert Opin. Biol. Ther. (2005) 5(7):953-965.
24. WILBURN SQ, EIJKEMANS G: Preventing needlestick injuries among healthcare workers: a WHO-ICN collaboration. Int. J. Occup. Environ. Health (2004) 10(4):451-456.
25. SENDI P, LOCHER R, BUCHELI B, BATTEGAY M: Intranasal influenza vaccine in a working population. Clin. Infect. Dis. (2004) 38(7): 974-980.
26. NIR Y, PAZ A, SABO E, POTASMAN I: Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. (2003) 68(3):341-344.
27. EFE E, OZER ZC: The use of breast-feeding for pain relief during neonatal immunization injections. Appl. Nurs. Res. (2007) 20(1):10-16.
28. DAGAN R, ESKOLA J, LECLERC C, LEROY O: Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. (1998) 66(5):2093-2098.
29. MALLET E, BELOHRADSKY BH, LAGOS R et al.: A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine (2004) 22(11-12):1343-1357.
30. WEN SX, TEEL LD, JUDGE NA, O'BRIEN AD: A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA (2006) 103(18):7082-7087.
31. MCKENZIE R, WALKER RI, NABORS GS et al.: Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine (2006) 24(18):3735-3745.
32. QADRI F, AHMED T, AHMED F et al.: Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6 - 17 months of age: dosing studies in different age groups. Vaccine (2006) 24(10):1726-1733.
33. CRIPPS AW, PEEK K, DUNKLEY M et al.: Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect. Immun. (2006) 74(2):968-974.
34. RYDELL N, STERTMAN L, STALENHEIM G, SJOHOLM I: Use of an oral diphtheria vaccine in human. Vaccine (2006) 24(33-34):5928-5930.
35. THIEM VD, DEEN JL, VON SL et al.: Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine (2006) 24(20):4297-4303.
36. ANH DD, CANH DG, LOPEZ AL et al.: Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine (2007) 25(6)1149-1155.
37. LYCKE N: From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol. (2004) 6(1):23-32.
38. PAUL Y: Some exaggerated or non-existing properties of OPV. Indian J. Community Med. (2007) 30(4):152-152.
39. YONEYAMA T, YOSHIDA H, SHIMIZU H et al.: Neurovirulence of Sabin 1-derived polioviruses isolated from an immunodeficient patient with prolonged viral excretion. Dev. Biol. (Basel.) (2001) 105:93-98.
40. ABD EL GHANY M, JANSEN A, CLARE S et al.: Candidate live, attenuated Salmonella enterica serotype Typhimurium vaccines with reduced fecal shedding are immunogenic and effective oral vaccines. Infect. Immun. (2007) 75(4):1835-1842.
41. FAVRE D, VIRET JF: Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. Vaccine (2006) 24(18):3856-3864.
42. MURPHY TV, GARGIULLO PM, MASSOUDI MS et al.: Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. (2001) 344(8):564-572.
43. O'RYAN M: Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev. Vaccine (2007) 6(1):11-19.
44. VESIKARI T, MATSON DO, DENNEHY P et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. (2006) 354(1):23-33.
45. +T cells for long-term pulmonary protection against influenza. Eur. J. Immunol. (2006) 36(3):770-778.
46. BJARNARSON SP, JAKOBSEN H, DEL GG et al.: The advantage of mucosal immunization for polysaccharide-specific memory responses in early life. Eur. J. Immunol. (2005) 35(4):1037-1045.
47. ZHANG Q BERNATONIENE J, BAGRADE L et al.: Regulation of production of mucosal antibody to pneumococcal protein antigens by T-cell-derived γ-IFN and interleukin-10 in children. Infect. Immun. (2006) 74(8):4735-4743.
48. RHARBAOUI F, WESTENDORF A, LINK C et al.: The Mycoplasma-derived macrophage-activating 2-kDa lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect. Immun. (2004) 72(12):6978-6986.
49. BECKER PD, FIORENTINI S, LINK C et al.: The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine (2006) 24(25):5269-5276.
50. BECKER PD, BERTOT GM, SOUSS D et al.: Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect. Immun. (2007) 75(4):1778-1784.
51. BETANCOURT AA, DELGADO CA, ESTEVEZ ZC et al.: Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J Infect. Dis. (2007) (In Press).
52. STEPHENSON I, ZAMBON MC, RUDIN A et al.: Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. (2006) 80(10):4962-4970.
53. SAMDAL HH, BAKKE H, OFTUNG F et al.: A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvanta. Hum. Vaccines (2005) 1(2):85-90.
54. BAKKE H, SETEK TN, HUYNH PN et al.: Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory. Vaccine (2004) 22(17-18):2278-2284.
55. TAMMIRUUSU A, PENTTILA T, LAHESMAA R et al.: Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model. Vaccine (2007) 25(2):283-290.
56. MUTSCH M, ZHOU W, RHODES P et al.: Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. (2004) 350(9):896-903.
57. BELSHE RB, EDWARDS KM, VESIKARI T et al.: Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. (2007) 356(7):685-696.
58. FLEMING DM, CROVARI P, WAHN U et al.: Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. J. (2006) 25(10):860-869.
59. WILLIAMS J, FOX-LEYVA L, CHRISTENSEN C et al.: Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine (2000) 18(18):1939-1943.
60. PARENT DC I, LANG J, SCHLUMBERGER M et al.: Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule investigators group. Vaccine (1997) 15(4):449-458.
61. ARORA A, HAKIM I, BAXTER J et al.: Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc. Natl. Acad. Sci. USA (2007) 104(11):4255-4260.
62. CHEN D, WEIS KF, CHU Q et al.: Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. (2001) 75(23):11630-11640.
63. DEAN HJ, CHEN D: Epidermal powder immunization against influenza. Vaccine (2004) 23(5):681-686.
64. CHEN D, MAA YF, HAYNES JR: Needle-free epidermal powder immunization. Expert Rev. Vaccines (2002) 1(3):265-276.
65. MAA YF, AMERI M, SHU C et al.: Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment. Curr. Drug Deliv. (2007) 4(1):57-67.
66. LIU Y, KENDALL AF: Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol. Bioeng. (2007) 97(5): 1300-1308.
67. MATRIANO JA, CORMIER M, JOHNSON J et al.: Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. (2002) 19(1):63-70.
68. MIKSZTA JA, DEKKER JP III, HARVEY NG et al.: Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. (2006) 74(12):6806-6810.
69. AUEWARAKUL P, KOSITANONT U, SORNSATHAPORNKUL P et al.: Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine (2007) 25(4):659-663.
70. GLENN GM, TAYLOR DN, LI X et al.: Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. (2000) 6(12):1403-1406.
71. GLENN GM, VILLAR CP, FLYER DC et al.: Safety and immunogenicity of an ETEC vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun. (2007) 75(5):2163-2170.
72. GLENN GM, KENNEY RT, ELLINGSWORTH LR et al.: Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines (2003) 2(2):253-267.
73. GUEBRE-XABIER M, HAMMOND SA, EPPERSON DE et al.: Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. (2003) 77(9):5218-5225.
74. FINGERUT E, GUTTER B, GOLDWAY M, ELIAHOO D, PITCOVSKI J: B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet. Immunol. Immunopathol. (2006) 112(3-4):253-263.
75. MORAVEC T, SCHMIDT MA, HERMAN EM, WOODFORD-THOMAS T: Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its Immunogenicity as an oral vaccine. Vaccine (2007) 25(9):1647-1657.
76. CHEN Y, SHEN Y, GUO X et al.: Transdermal protein delivery by a coadministered peptide identified via phage display. Nat. Biotechnol. (2006) 24(4):455-460.
77. HONEYWELL-NGUYEN PL, WOUTER GROENINK HW, DE GRAAFF AM, BOUWSTRA JA: The in vivo transport of elastic vesicles into human skin: effects of occlusion, volume and duration of application. J. Control. Rel. (2003) 90(2):243-255.
78. PAUL A, CEVC G, BACHHAWAT BK: Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine (1998) 16(2-3):188-195.
79. MISHRA D, DUBEY V, ASTHANA A, SARAF DK, JAIN NK: Elastic liposomes mediated transcutaneous immunization against hepatitis B. Vaccine (2006) 24(22):4847-4855.
80. CEVC G, BLUME G: Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim. Biophys. Acta (1992) 1104(1):226-232.
81. MIKSZTA JA, ALARCON JB, BRITTINGHAM JM et al.: Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery Nat. Med. (2002) 8(4):415-419.
82. GILL HS, PRAUSNITZ MR: Coated microneedles for transdermal delivery. J. Control. Rel. (2006) 117(2):227-237.
83. TEO MA, SHEARWOOD C, NG KC, LU J, MOOCHHALA S: In vitro and in vivo characterization of MEMS microneedles. Biomed. Microdev. (2005) 7(1):47-52.
84. MIKSZTA JA, SULLIVAN VJ, DEAN C et al.: Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. (2005) 191(2):278-288.
85. RYAN ET, CALDERWOOD SB, QADRI F: Live attenuated oral cholera vaccines. Expert Rev. Vaccines (2006) 5(4):483-494.
86. GENTSCHEV I, SPRENG S, SIEBER H et al.: Vivotif - a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens. Chemotherapy (2007) 53(3):177-180.
87. WAHID R, SALERNO-GONCALVES R, TACKET CO, LEVINE MM, SZTEIN MB: Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine (2007) 25(8):1416-1425.
88. KHAN S, CHATFIELD S, STRATFORD R et al.: Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine (2007) 25(21):4175-4182.
89. ANGELAKOPOULOS H, HOHMANN EL: Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. (2000) 68(4):2135-2141.
90. TURNER AK, BEAVIS JC, STEPHENS JC et al.: Construction and Phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect. Immun. (2006) 74(2):1062-1071.
91. ZHAO X, ZHANG M, LI Z, FRANKEL FR: Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J. Virol. (2006) 80(18):8880-8890.
92. LEE JS, POO H, HAN DP et al.: Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. (2006) 80(8):4079-4087.
93. RAMASAMY R, YASAWARDENA S, ZOMER A et al.: Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine (2006) 24(18):3900-3908.
94. TACKET CO, MASON HS, LOSONSKY G et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. (1998) 4(5):607-609.
95. THANAVALA Y, MAHONEY M, PAL S et al.: Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. USA (2005) 102(9):3378-3382.
96. KENDE M, TAN X, WLAZLOWSKI C et al.: Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72. Vaccine (2007) 25(16):3219-3227.
97. KENDE M, DEL GG, RIVERA N, HEWETSON J: Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine (2006) 24(12):2213-2221.
98. KOTLOFF KL, SZTEIN MB, WASSERMAN SS et al.: Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. (2001) 69(6):3581-3590.
99. PICKERING RJ, SMITH SD, STRUGNELL RA, WESSELINGH SL, WEBSTER DE: Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine (2006) 24(2):144-150.
100. RIEMER AB, UNTERSMAYR E, KNITTELFELDER R et al.: Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. (2007) 67(7):3406-3411.
101. MIELCAREK N, DEBRIE AS, RAZE D et al.: Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. (2006) 2(7):E65.
102. AMIDI M, ROMEIJN SG, VERHOEF JC et al.: N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine (2007) 25(1):144-153.
103. RAVICHANDRAN E, AL-SALEEM FH, ANCHARSKI DM et al.: A trivalent vaccine against Botulinum toxin (serotypes A, B and E) that can be administered by the mucosal route. Infect. Immun. (2007) 75(6):3043-3054.
104. ZENG M, XU Q, PICHICHERO ME: Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine (2007).
105. DIGIANDOMENICO A, RAO J, HARCHER K et al.: Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. USA (2007) 104(11):4624-4629.
106. DUVERGER A, JACKSON RJ, VAN GINKEL FW et al.: Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J. Immunol. (2006) 176(3):1776-1783.
107. HANNIFFY SB, CARTER AT, HITCHIN E, WELLS JM: Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J. Infect. Dis. (2007) 195(2):185-193.
108. HINKULA J, DEVITO C, ZUBER B et al.: A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine (2006) 24(21):4494-4497.
109. KAMINSKI RW, TURBYFILL KR, OAKS EV: Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immun. (2006) 74(5):2856-2866.
110. LEE SE, KIM SY, JEONG BC et al.: A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun. (2006) 74(1):694-702.
111. MIZUNO D, IDE-KURIHARA M, ICHINOMIYA T, KUBO I, KIDO H: Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J. Immunol. (2006) 176(2):1122-1130.
112. EBENSEN T, SCHULZE K, RIESE P, MORR M, GUZMAN CA: The bacterial second messenger cdiGMP exhibits promising activity as mucosal adjuvant. Clin. Vaccine Immunol. (2007) 14(8): 952-958.
113. SINGH SR, HULETT K, PILLAI SR et al.: Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine (2006) 24(8):1213-1224.
114. PIMENTA FC, MIYAJI EN, AREAS AP et al.: Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice. Infect. Immun. (2006) 74(8):4939-4944.
115. SLOAT BR, CUI Z: Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. (2006) 23(6):1217-1226.
116. SARDINAS G, REDDIN K, PAJON R, GORRINGE A: Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. Vaccine (2006) 24(2):206-214.
117. TREANOR J, NOLAN C, O'BRIEN D et al.: Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine (2006) 24(3):254-262.
118. AGNELLO D, HERVE CA, LAVAUX A et al.: Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J. Virol. (2006) 80(8):3823-3832.
119. JERTBORN M, NORDSTROM I, KILANDER A, CZERKINSKY C, HOLMGREN J: Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. (2001) 69(6)4125-4128.
120. KOZLOWSKI PA, CU-UVIN S, NEUTRA MR, FLANIGAN TP: Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. (1997) 65(4)1387-1394.
121. PECHINE S, JANOIR C, BOUREAU H et al.: Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine (2007) 25(20):3946-3954.
122. BLACK CA, ROHAN LC, COST M et al.: Vaginal mucosa serves as an inductive site for tolerance. J. Immunol. (2000) 165(9):5077-5083.
123. KOZLOWSKI PA, WILLIAMS SB, LYNCH RM et al.: Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. (2002) 169(1):566-574.
124. HOPKINS WJ, ELKAHWAJI J, BEIERLE LM, LEVERSON GE, UEHLING DT: Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a Phase II clinical trial. J. Urol. (2007) 177(4):1349-1353.
125. LUCI C, HERVOUET C, ROUSSEAU D et al.: Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J. Immunol. (2006) 176(5):2749-2757.
126. CUTTS FT, CLEMENTS CJ, BENNETT JV: Alternative routes of measles immunization: a review. Biologicals (1997) 25(3):323-338.
127. WONG-CHEW RM, ISLAS-ROMERO R, GARCIA-GARCIA ML et al.: Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine (2006) 24(5):683-690.
128. AMIDI M, PELLIKAAN HC, HIRSCHBERG H et al.: Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine (2007) (In Press).
129. BENMOHAMED L, BELKAID Y, LOING E et al.: Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. (2002) 32(8):2274-2281.
130. NESBURN AB, BETTAHI I, ZHANG X et al.: Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. (2006) 4(4):178-187.
131. WIDERA G, JOHNSON J, KIM L et al.: Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine (2006) 24(10):1653-1664.
132. VERBAAN FJ, BAL SM, VAN DEN BERG DJ et al.: Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. J. Control. Rel. (2007) 117(2):238-245.
133. SHIRKHANZADEH M: Microneedles coated with porous calcium phosphate ceramics: effective vehicles for transdermal delivery of solid trehalose. J. Mater. Sci. Mater. Med. (2005) 16(1):37-45.
134. TEZEL A, PALIWAL S, SHEN Z, MITRAGOTRI S: Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine (2005) 23(29):3800-3807.
135. BRAMSON J, DAYBALL K, EVELEGH C et al.: Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. (2003) 10(3):251-260.
136. ZHAO YL, MURTHY SN, MANJILI MH et al.: Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine (2006) 24(9):1282-1290.
137. MISRA A, GANGA S, UPADHYAY P: Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine (1999) 18(5-6):517-523.
138. ZHANG L, NOLAN E, KREITSCHITZ S, RAHUSSAY DP: Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim. Biophys. Acta (2002) 1572(1):1-9.
139. HOOPER JW, GOLDEN JW, FERRO AM, KING AD: Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine (2007) 25(10):1814-1823.